52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Aspen Pharmacare Sells Japanese Ops To Sandoz For Up To Eur 400 Mln
Sandoz Receives FDA Approval For Oncology Supportive Care Ziextenzo
Novartis Says FDA Placed Partial Hold On Avxs-101 Intrathecal Trials For SMA Patients
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Independent Non-Executive Chairman of the Board
Honorary Chairman of the Board
Daniel L. Vasella
Honorary Chairman of the Board
Chief Executive Officer, Member of the Executive Committee
Independent Non-Executive Vice Chairman of the Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR MAYZENT® (SIPONIMOD) FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)
* NEW NOVARTIS PREVENT DATA SHOW COSENTYX DELIVERS EARLY RELIEF IN AXIAL SPONDYLOARTHRITIS
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function in a key study.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.
Novartis <NOVN.S> is buying the Japanese generics unit of South Africa's Aspen Pharmacare <APNJ.J> in a deal worth up to 400 million euros ($440.80 million) to expand in the world's third-biggest drug market, the Swiss drugmaker said on Monday.
Aspen Pharmacare Holdings agreed to sell its Japanese operations to Novartis' Sandoz for up to 400 million euros ($440.80 million) through a unit as it looks to cut debt, the South African drugmaker said on Monday.
Novartis' Sandoz generic drug unit is buying Aspen's Japanese operations for an initial payment of 300 million euros ($330.60 million) to expand in the world's third-biggest generic medicines market, the Swiss drugmaker said on Monday.
Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill battle to sell copies of rivals' blockbusters in the world's top drug market.
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis.
A clinical trial of Novartis's Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.
U.S. regulators have halted a trial of Novartis's Zolgensma treatment after an animal study raised safety concerns, the company said on Wednesday, in a setback for the drugmaker's plan to expand its use to older patients.
* FDA PLACED A PARTIAL HOLD ON AVXS-101 INTRATHECAL CLINICAL TRIALS FOR SMA PATIENTS BASED ON FINDINGS IN A SMALL PRE-CLINICAL ANIMAL STUDY
* NOVARTIS RECEIVES APPROVAL FOR COSENTYX LABEL UPDATE IN EUROPE TO INCLUDE DOSING FLEXIBILITY IN ANKYLOSING SPONDYLITIS Source text for Eikon: Further company coverage: (Berlin Speed Desk)
* PLIANT THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION TO DEVELOP NOVEL THERAPIES FOR NASH AND FIBROTIC DISEASES
Novartis sales data on Tuesday suggested the Swiss drugmaker is reaping less than the $2.1 million U.S. list price for its gene therapy Zolgensma, as insurers may be getting breaks on the world's most-expensive one-time treatment.
Swiss drugmaker Novartis <NOVN.S> boosted its 2019 forecasts on Tuesday after beating third-quarter expectations, a feat helped by the sales debut of gene therapy Zolgensma, the world's most expensive one-time treatment.
* SANDOZ Q3 OPERATING INCOME WAS USD 191 MILLION (-47%, -42% CC) IMPACTED BY CHANGES IN LEGAL SETTLEMENT PROVISIONS, HIGHER NET MANUFACTURING AND SANDOZ TRANSFORMATION RESTRUCTURING EXPENSES AND LOWER DIVESTMENT INCOME
Swiss drugmaker Novartis on Tuesday boosted its full-year targets, with sales now expected to grow at a high single-digit percentage rate and core operating income now seen growing at a mid- to high-teen rate.
Novartis's anti-blindness medicine Beovu has become the latest eye drug to win U.S. Food and Drug Administration approval, giving the Swiss drugmaker a boost in the increasingly competitive market for eye problems among an aging population.
Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss, the Swiss pharmaceuticals company said on Tuesday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.